Navigation Links
New treatment for advanced prostate cancer
Date:7/29/2008

Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.

Professor Wayne Tilley and Dr Lisa Butler of the University's Dame Roma Mitchell Cancer Research Laboratories have discovered that by using existing prostate cancer drugs in combination with new drugs at lower doses, they can expect to generate better results for patients than current treatments.

Growth of prostate cancer is initially dependent on hormones called androgens, which traditionally have been suppressed to stop tumour growth. However, despite an initial response, resistance to hormone deprivation often occurs and the tumour starts to grow again, Professor Tilley says.

"Men undergoing hormone deprivation therapy can also experience significant side effects, including reduced libido, impotence, hot flushes, tiredness and sweating, gradual decrease in body hair, reduced bone and muscle strength and cognitive changes," he adds.

Professor Tilley and Dr Butler have successfully killed prostate cancer cells in laboratory studies using low doses of a combination therapy of drugs including bicalutamide (an anti-androgen that opposes the action of androgen on the tumour), and the inhibitors 17AAG and vorinostat.

These new drugs block key cancer survival pathways, but are not particularly effective in killing prostate cancer cells if given alone.

"We can now confirm that a very low level of bicalutamide is capable of inhibiting cancer cell proliferation by more than 10-fold when combined with either vorinostat or 17AAG, making our current treatments much more effective and causing fewer side effects," says Dr Lisa Butler.

All the drugs needed for combination therapy are already approved for use in clinical trials, so the new therapy can be readily tested in patients with advanced prostate cancer.

Professor Chris Sweeney, a world recognised medical oncologist and Director of Clinical Trials at the Royal Adelaide Hospital Cancer Centre, will lead a multidisciplinary team to test the new treatment.

"The ultimate test of this exciting laboratory breakthrough is to see if it improves outcomes and quality of life for men suffering from advanced prostate cancer," he says.

"The strong partnership between medical scientists and clinicians at the University of Adelaide and the Royal Adelaide Hospital means patients can benefit from advances in medical science much faster than in the past."


'/>"/>

Contact: Wayne Tilley
wayne.tilley@adelaide.edu.au
61-882-223-252
University of Adelaide
Source:Eurekalert

Related medicine news :

1. New therapy for HIV treatment
2. Alzheimers Treatment Trials May Have Special Challenges
3. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
4. Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi
5. Researchers disprove long-standing belief about HIV treatment
6. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
7. Clinical Trial Concluded For New Wrinkle Treatment
8. Has cancer spread? Research identifies best way to find answers so treatment can begin
9. Minimally Invasive Treatment Improves Male Fertility
10. Minimally invasive treatment improves male fertility
11. Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
(Date:2/23/2017)... ... 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. ... Not to Hot,” which will begin airing on February 24, 2017. The show chronicles ... the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... 2017 Obese people are seldom ... varicose veins in their body. The rising number of ... adoption of endovenous laser therapy for treatment of varicose ... therapy market, published by Future Market Insights, indicates ... consequences of obesity have collectively factored the growth in ...
Breaking Medicine Technology: